Combining anti-IL-18 with anti-PD1 therapy effectively reduced levels of G-MDSC and M-MDSC, enhancing T cell infiltration and immune function, providing a new strategy for osteosarcoma immunotherapy (Guan et al., 2017). Here, IL18 is linked to osteosarcoma.